Compare MYGN & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYGN | NCV |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 373.7M |
| IPO Year | 1996 | N/A |
| Metric | MYGN | NCV |
|---|---|---|
| Price | $4.00 | $16.17 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $7.64 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 55.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $2.74 | $14.46 |
| 52 Week High | $8.59 | $17.65 |
| Indicator | MYGN | NCV |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 43.17 |
| Support Level | $2.89 | $15.55 |
| Resistance Level | $5.42 | $16.28 |
| Average True Range (ATR) | 0.24 | 0.31 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 85.20 | 50.79 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.